The frequency of SATB2-negative tumours reported here is lower than that in the study by Magnusson et al (2011), but in that study only ∼10% of the tumours had metastatic disease compared with ∼17% in this cohort, which might in part explain these differences, although SATB2 expression was not found to be significantly associated with M stage, only T and N stage, in this study. The gene discussed is SATB2; the disease is metastatic neoplasm.